

China Pharmaceutical & Biotechnology Monthly

April 2009

Tracking China Healthcare

Vol. 25

Saving Lives and Livers

March 2009 must have been an especially hectic one for China's hepatologists. Even as The Chinese Society of Hepatology was busy launching a major initiative to uncover reasons behind high levels of treatment non-compliance in the hepatitis B (HBV) patient community, two separate hepatitis C (HCV) contamination scandals involving blood transfusions and hemodialysis centers were made public. China has the world's largest numbers of patients with chronic viral hepatitis (both B and C). While the two causative agents are entirely differ-

ent viral entities (one a partially doubled-stranded (DNA) hepadnavirus, the other an RNA Flavivirus), both share long-term sequelae in common, most notably cirrhosis and hepatocellular carcinoma (HCC), that place a significant disease burden on the Chinese population. GBI examines the hepatitis B and C markets in China, including the new classes of small molecule drugs, and considers the current and future landscape for these treatments.

[Continued on page 2](#)

Inside This Month:

Partial list of contents

Top Stories P1

Saving Lives and Livers
.....

Reform Rollout
.....

Carl Firth on China Deals

Key Facts and Figures P19

2009 Healthcare budget
SOURCE Statistics

Deals P20

Notable deals announced during the month of April

Product Watch P21

SFDA approvals for unique drug applications in March

General P22

IMS reduces global pharma forecast, emerging markets incl. China play larger roles

Policy & Regulations P26

Doc holidays gunned down- Shandong MDs corralled to work at clinics on weekends

Investment & Finance P30

Sanofi-Aventis to invest RMB 870 million to build new China facilities
.....

PE/VC investment in biopharmaceutical sector pops in Q1 after slower 2008
.....

Mingyuan acquires 95% of mo-bio specialist Genetel for HKD 280 million

Company P33

Huya to identify promising drug candidates for Abbott
.....

Eli Lilly to pursue partnerships for expansion in China

Product & Pipeline P37

Sinovac Receives RMB 87 Million Purchase Order for Healive from China's Ministry of Public Health
.....

First approval granted for drug with lupus nephritis indication in China

Research & Development P39

Scottish stem cell center lochs down agreement with Peking University

Therapeutic Area P40

Gates Foundation teams up with MOH, makes grant to fight TB in China

Hospital P41

Guangdong hospitals make switch from public to private

Research Highlights /43

April 2009 Publications

People /44

Carl Firth, Head of Asia Healthcare, Bank of America Merrill Lynch, Hong Kong
Shujun Cheng, Professor, Department of Etiology and Chemical Carcinogenesis, Cancer Institute (Hospital), CAMS and PUMC

Company Profile /45

Zhengjiang Jingxin Pharmaceutical

Product Profile /47

Acarbose

Equity Market Review /48

Shanghai A
Shenzhen A
HK / SINGAPORE
NYSE / NASDAQ

Events /52

May - June 2009